Search the Newsreel

Capricor Therapeutics: FDA Advisory Panel Votes 9-3 That Evidence Does Not Support Deramiocel for DMD Cardiomyopathy

An FDA advisory committee voted 9-3 that the available evidence does not support the effectiveness of Deramiocel for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. While this recommendation is non-binding, the FDA will consider it as part of the Biologics License Application (BLA) review, with the …

Could Capral (ASX:CAA) Lead a Sharper Sector Read?

Capricorn Energy Confirms Share Capital and Voting Rights Update

Levi & Korsinsky Announces Investigation of Securities Claims Against Capricor Therapeutics, Inc. (CAPR)

Levi & Korsinsky has launched an investigation into Capricor Therapeutics, Inc. (CAPR) following a significant stock drop. The drop occurred after FDA briefing documents raised concerns about the cardiac efficacy of Deramiocel and revealed a change in the statistical analysis plan. The firm is …

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Capricor Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for Duchenne muscular dystrophy cardiomyopathy, with 9 votes against and 3 for. Despite the non-binding negative vote on a narrow …

Capricorn Energy PLC Revenue Breakdown – LSE:CNE

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

ATLANTA, July 30, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 27, 2026, STATNews reported that: “The Food and Drug Administration said Monday that Capricor …

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

Hagens Berman has opened an investigation into Capricor Therapeutics (NASDAQ: CAPR) following a significant stock crash after the FDA questioned the company's claims regarding its Duchenne muscular dystrophy drug. The FDA's briefing document revealed discrepancies between Capricor's characterization of its Phase 3 HOPE-3 trial …

Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (“Capricor” or the “Company”) for potential violations of the federal securities laws. On July 27, …

Capricor stock downgraded at Oppenheimer (CAPR:NASDAQ)

Oppenheimer downgraded Capricor Therapeutics (CAPR) after an FDA advisory committee voted against endorsing its lead drug, Deramiocel. This news caused Capricor's stock to drop over 45%, reaching a new 52-week low.

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy

Capricor Therapeutics' stock fell sharply after an FDA advisory panel overwhelmingly rejected the sufficiency of evidence supporting its Duchenne muscular dystrophy cell therapy, Deramiocel. The panel's decision echoed FDA staff concerns regarding post hoc changes to key analyses after the late-stage trial. This rejection …

Duchenne Therapy Has Aug. 22 FDA Action Target After Panel Vote

Capricor Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against the effectiveness of Deramiocel for cardiomyopathy in Duchenne muscular dystrophy (DMD). This non-binding vote focused on a narrower indication than proposed, with the company noting supportive discussion on …

FDA Panel Says "No" To Capricor's DMD Drug Deramiocel, Citing "Fragile" Data; Shares Plunge

(RTTNews) - Shares of Capricor Therapeutics, Inc. (CAPR) have been hit hard this week following adverse regulatory developments related to Deramiocel, the company's investigational cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy. Duchenne muscular dystrophy (DMD) is a devastating genetic disorder characterized by progressive weakness …

Capricor Duchenne cell therapy voted down by FDA panel

An FDA advisory panel voted against Capricor Therapeutics' experimental cell therapy, deramiocel, for Duchenne muscular dystrophy-related cardiomyopathy, citing insufficient evidence of effectiveness. This decision follows a contentious regulatory process and skepticism from FDA scientists regarding Capricor's data analysis. The FDA is expected to make …

UBS Remains a Buy on Capricorn Metals Ltd (CMM)

Capri Global Capital AUM Grows 62% In Q1 FY27

CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Capricor and would like to discuss your legal rights, contact Bragar Eagel …

Capri Holdings Is Maintained at Hold by TD Cowen

TD Cowen has maintained its "Hold" rating on Capri Holdings. This indicates the firm's neutral stance on the company's stock, suggesting investors should continue to hold their existing positions without buying more or selling.

FDA panel votes against Capricor's Duchenne heart disease therapy

A U.S. FDA advisory panel voted against the effectiveness data for Capricor Therapeutics' experimental cell therapy, deramiocel, intended for a heart condition associated with Duchenne muscular dystrophy. The nine-to-three vote mirrored FDA staff concerns regarding insufficient evidence of efficacy and questioned changes in key …

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics announced that The Lancet has published results from its pivotal Phase 3 HOPE-3 clinical trial for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The study demonstrated a significant 54% slowing of upper limb function decline and clinically meaningful cardiac …

Analysts Estimate Capri Holdings (CPRI) to Report a Decline in Earnings: What to Look Out for

Capri Holdings (CPRI) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare …

Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

The FDA is holding advisory committee meetings for therapies from Capricor Therapeutics and Replimune, with briefing documents indicating potential challenges for approval. Meanwhile, Q2 earnings reports continue with GSK announcing a $2.5 billion cost-cutting plan and AstraZeneca affirming its 2030 revenue target of $80 …

Capri Global Capital Profit Doubles to Rs 353 Cr in Q1

Capri Global Capital hosts Q1FY27 investor call on Aug 3

Capri Global Capital Q1 Results: Earnings call recording available online

Capri Global Capital Teams Up With OpenAI to Implement Advanced AI in Lending Operations

Earnings call transcript: Capri Global Capital posts strong Q1 2026 growth

Capri (CPRI) Expected to Post Quarterly Earnings on Wednesday

Capral (ASX:CAA): Can Earnings and Net Cash Narrow Its Discount to Asset Backing?

Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?

CAPR INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The investigation concerns whether the Company and/or members of its senior management may have violated …

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP

Glancy Prongay Wolke & Rotter LLP has initiated a securities fraud investigation into Capricor Therapeutics, Inc. (CAPR) following a critical FDA review. The FDA's briefing documents raised concerns about the scientific justification and accuracy of Capricor's data collection for its cell therapy, concluding that …

CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation

Kehoe Law Firm, P.C. is investigating potential securities claims against Capricor Therapeutics, Inc. (NASDAQ:CAPR) after the company's stock price fell over 60% due to FDA concerns regarding the effectiveness data for its cell therapy, deramiocel. The FDA raised issues about Capricor changing how it …

Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR)

Capricor Therapeutics has been downgraded to Sell due to mounting FDA doubts regarding the efficacy of its lead product candidate, deramiocel, for DMD cardiomyopathy. The FDA noted that positive endpoints for their HOPE-3 trial were only achieved after post-unblinding SAP changes, compromising statistical validity. …

This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward

Capri Holdings Ltd (CPRI) Institutional Confidence

Capri Holdings Ltd (CPRI) has an institutional shareholding score of 10.00, ranking 1st in the Specialty Retailers industry. The institutional shareholding proportion is 108.35%, indicating a 17.62% decrease quarter-over-quarter. David Einhorn is the largest institutional shareholder, holding 4.75 million shares.